【24h】

POLYMERIC BIOMATERIALS IN MEDICA L SYSTEMS

机译:MEDICA L系统中的聚合物生物材料

获取原文
获取原文并翻译 | 示例

摘要

As demonstrated above, polymeric biomaterials which have been practically applied to patient treatments are restricted to a small number of polymers, although a huge number of polymers have been used in industry. However, this is not surprising because the priority of biomaterials used in the medical system is non-toxicity and hence regulatory authorities as well as medical society become very conservative in using new biomaterials if they have no previous experience in clinical applications. It should be also mentioned that surface modification and chemical derivatization of polymers are not always welcome by medical device industries, since they consider the cost-effectiveness of biomaterials the most important and want to concentrate their effort on the reduction of device price. This attitude of regulatory, medical, and industrial societies outside the biomaterials science would often discourage young biomaterials scientists.
机译:如上所述,尽管工业上已经使用了大量的聚合物,但是实际上已应用于患者治疗的聚合物生物材料仅限于少量的聚合物。然而,这不足为奇,因为在医学系统中使用的生物材料的优先级是无毒的,因此,如果没有新的生物材料在临床上的应用经验,监管机构和医学界在使用新的生物材料时会变得非常保守。还应该指出,医疗器械行业并不总是欢迎聚合物的表面改性和化学衍生化,因为它们认为生物材料的成本效益最为重要,并希望将精力集中在降低器械价格上。生物材料科学之外的监管,医学和工业社会的这种态度通常会阻止年轻的生物材料科学家。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号